All episodes

34 min

Real-World Perspectives on Switching Patients With Multiple Sclerosis From Anti-CD20 Therapy to Cladribine Tablets...

Real-World Perspectives on Switching Patients With Multiple Sclerosis From Anti-CD20 Therapy to Cladribine Tablets From US-Based Advanced Practice Providers: A Podcast

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03391-5. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as...

47 min

Treatment in R/M-SCCHN in the Year 2025 - Standard and Considerations for am Individualized Treatment

A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025—Standard and Considerations for an Individualized Treatment

In this podcast, speakers Dr Konrad Klinghammer and Dr Philipp Ivanyi discuss the general principles of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), with a focus on key phase 3 clinical trials such as KEYNOTE-048 and EXTREME. The strengths and limitations of these studies are evaluated, and in the context of additional phase 2 trials, considerations are made regarding individualised treatment strategies based on patient-specific characteristics when selecting first-line therapy. Second-line treatment decisions...

31 min

Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion

Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03400-7. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original...

29 min

Exploring two new, validated disease specific outcome measures to assess severity of Chronic Hand Eczema

This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the Dermatology and Therapy website and by using this link:https://link.springer.com/article/10.1007/s13555-025-01551-7. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and...

45 min

Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast

Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast

In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed, supplemented with additional reflections from the European Hematology Association (EHA) 2025 Congress. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of multiple myeloma (MM). This podcast is intended to broaden the reach of complex data on MM from these scientific meetings to a broader audience, including nonspecialists, helping enable better informed...

18 min

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib for EGFR-Mutated NSCLC

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast

Dr. Balazs Halmos and Dr. Melissa Johnson present the phase 2b COPERNICUS study evaluating subcutaneous amivantamab, with lazertinib as first-line treatment, or with chemotherapy as second-line treatment for EGFR-mutated non-small cell lung cancer.The intent of this vodcast is to review the study design for COPERNICUS, highlighting how it combines pragmatic elements to assess the efficacy and safety of subcutaneous amivantamab with supportive care for prevention and management of adverse events in a diverse...

39 min

Updates to the European Renal Best Practice and UK Kidney Association Guidelines for Treatment of Anemia in CKD

Podcast Synopsis of Updates to the European Renal Best Practice and UK Kidney Association Guidelines for Treatment of Anaemia in Chronic Kidney Disease

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03366-6. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access. This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or...

30 min

Lung Health & RSV: Podcast of a Patient–Physician Discussion Based on Insights from a Patient Advisory Board Meeting

Lung Health and Respiratory Syncytial Virus: Podcast of a Patient–Physician Discussion Based on Insights from a Patient Advisory Board Meeting

This podcast is published open access in Infectious Diseases and Therapy and is fully citeable. You can access the original published podcast article through the Infectious Diseases and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40121-025-01216-0. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access
This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format,...

27 min

The Role of Oncology Nurses and Advanced Practice Providers in the Treatment of Patients With HRR-Deficient mCRPC

The Role of Oncology Nurses and Advanced Practice Providers in the Treatment of Patients With HRR-Deficient mCRPC Receiving Talazoparib Plus Enzalutamide: A Podcast

This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00376-w. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or...

25 min

Managing Drug Interactions with Enzalutamide in Patients with Prostate Cancer: A Podcast

Managing Drug Interactions with Enzalutamide in Patients with Prostate Cancer

This podcast is published open access in Drug Safety and is fully citeable. You can access the original published podcast article through the Drug Safety website and by using this link: https://link.springer.com/article/10.1007/s40264-025-01600-2.

All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,...